Biotechs Benefit From Pharma Deals And Dollars

Big pharma companies may be under pressure to buy like-sized peers with late-stage clinical programs and marketed products, but several collaborations with and investments in biotechnology firms announced during the first few days of 2016 show that the world's largest drug makers also are focused on long-term prospects for their research and development pipelines.